- Quality of earnings on a lower-middle-market target runs $35,000 to $75,000 and legal starts around $50,000, so a sponsor who commissions the full slate on signing has committed $150,000 or more before testing the thesis.
- Staged diligence means spend follows certainty: each phase buys the information that justifies the next phase's spend, and every phase has a kill criterion written before it starts.
- Phase one costs time and no cash — reconstruct retention from primary documents, test add-backs across three years, map concentration on both the customer and supplier side, and read the top three contracts in full.
- Phase one done properly kills roughly a third of deals, before any recoverable money has been spent.
- No phase-two item should be commissioned without a written statement of which phase-one uncertainty it resolves.
- Capital partners look for evidence that a sponsor knows what they have not established yet; a sponsor who lists three open questions is more credible than one who lists none.
You are signing an LOI on a $22 million business with a 75-day exclusivity window. You have no committed capital. You have five family offices who have expressed interest and will each need to get comfortable independently. You have your own money funding the process, and if the deal breaks in week nine you eat every dollar you have spent.
A fund in the same position amortises a $50,000 platform contract across fifteen deals and staffs the analysis with two associates whose salaries are paid by management fees. You have neither. What you have instead is that you probably know this sector better than they do, and you can decide things in an afternoon that would take them a partners' meeting.
The question is how to convert that into a diligence process that a capital partner will underwrite.
The economics that should drive every decision
Most first-time sponsors get the sequencing wrong in a predictable direction: they spend on confirmatory work before they have done the work that would tell them whether confirmation is worth buying.
The arithmetic is unforgiving. Quality of earnings on a lower-middle-market target runs somewhere in the $35,000 to $75,000 range. Legal on a straightforward deal, $50,000 and up. Environmental, insurance, benefits, IT — each a five-figure item. A sponsor who commissions the full slate on signing has committed $150,000 or more against a deal with, realistically, a 60% chance of closing, and has done it before establishing whether the thesis survives contact with the numbers.
The discipline that fixes this is staged diligence, and it is now standard practice among sponsors who have done this more than twice. The principle is that spend follows certainty. Each phase buys the information needed to justify the next phase's spend, and every phase has an explicit kill criterion written before it starts.
Phase one: what you do yourself, in week one
This is the phase that has changed most, and it is the phase that determines whether the rest of the money is well spent.
Reconstruct the revenue story from the primary documents rather than the CIM. The CIM tells you what the banker wants you to conclude. The customer schedule, the contracts, and the monthly detail tell you whether it is true. Specifically: can you rebuild the retention figure from the underlying data, and if not, why not? A retention number you cannot reconstruct is the most common soft spot in a lower-middle-market process, and it is free to test.
Test the add-backs against three years, not one. Any adjustment that appears in consecutive years is not one-time, whatever the schedule calls it. This is arithmetic, it takes an hour, and it frequently moves the number the whole deal is priced off.
Map concentration on both sides. Customers and suppliers. Sponsors reliably examine the first and skip the second, and supplier concentration in a distribution or manufacturing business is at least as capable of destroying a thesis.
Read the top three customer contracts yourself, in full. Not the summaries. The renewal mechanism, the notice period, the assignment clause, and whether there is a change-of-control provision that turns your acquisition into a customer's option to leave.
Write down what would have to be true. Three to five falsifiable statements. "Retention above 90% on a dollar basis for the last three years." "Gross margin on the top product line has not declined more than 200 basis points." These become the kill criteria for phase two, and — this is the part that matters commercially — they become the document you send to capital partners.
Phase one costs you time and no cash. Done properly it kills perhaps a third of deals, and it kills them before you have spent anything recoverable.
Phase two: what you buy, and when
Once phase one has survived, spend follows the specific risks phase one identified rather than a standard slate.
If the revenue quality is the open question, buy the quality of earnings and scope it narrowly toward that question rather than accepting the standard engagement letter. If the contracts are the open question, buy three hours of the right lawyer's time rather than a full legal review. If the sector dynamics are the open question, buy expert calls, which are cheap relative to everything else here and which sponsors under-use.
The discipline is that no phase-two item gets commissioned without a written statement of which phase-one uncertainty it resolves. This sounds bureaucratic for a one-person shop. It is the difference between a $60,000 broken-deal cost and a $180,000 one.
Phase three: confirmatory, and only with capital aligned
The full slate, after your lead capital partner is committed in substance and the remaining diligence is confirming rather than discovering. If you are still discovering in phase three, phase one was not done properly.
What this looks like to a capital partner
Here is the part that is easy to miss when you are inside the process.
Family offices and independent sponsor funds see a great many sponsors. What separates the ones they back is rarely the deal — good deals get shown to everyone. It is whether the sponsor can demonstrate a method. A packet that shows what was tested, in what order, what was found, and what remains open reads entirely differently from one that presents a conclusion supported by a model.
The specific thing capital partners tell us they look for is evidence that the sponsor knows what they have not established yet. A sponsor who lists three open questions and how she intends to close them is more credible than one who lists none, because the second one either did not look or is not telling.
This is also the reason to run the same process on every deal even when your instinct is that a particular target is clean. The consistency is the asset. A sponsor on her fourth deal who can show a capital partner the same structured analysis on all four, including the two she passed on and why, is selling something other sponsors cannot.
The one-person constraint, honestly
None of this makes a sponsor equivalent to a fund with a deal team. It changes what the constraint binds on.
The bottleneck used to be the reading — one person, 400 documents, 75 days, with the capital raise running in parallel and every family office asking for a different cut of the same information. That bottleneck has genuinely moved. First-pass analysis that took a week now takes an afternoon, and the sponsor's time relocates to judgment and to the capital conversation, which is where a sponsor's advantage was always going to be.
What has not changed is that somebody has to know what should be in the room. The tooling reads faster. Deciding what to look for is still yours.
HuxleyIQ is available on trial for independent sponsors, including for a live deal.